Voting Rights and Shares Capital of the Company
Nanobiotix (NBTX) has released its latest voting rights and shares capital update as of January 31, 2025. The company reported 47,426,851 shares outstanding, with 49,208,659 theoretical voting rights and 49,186,541 exercisable voting rights.
Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France, dual-listed on Euronext Paris and Nasdaq Global Select Market. The company specializes in physics-based therapeutic approaches and owns more than 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.
Nanobiotix (NBTX) ha pubblicato il suo ultimo aggiornamento sui diritti di voto e sul capitale sociale al 31 gennaio 2025. L'azienda ha riportato 47.426.851 azioni in circolazione, con 49.208.659 diritti di voto teorici e 49.186.541 diritti di voto esercitabili.
Nanobiotix è un'azienda biotecnologica clinica in fase avanzata con sede a Parigi, Francia, quotata sia su Euronext Paris che sul Nasdaq Global Select Market. L'azienda si specializza in approcci terapeutici basati sulla fisica e possiede più di 25 famiglie di brevetti su tre piattaforme di nanotecnologia focalizzate su oncologia, biodisponibilità e biodistribuzione, e disturbi del sistema nervoso centrale.
Nanobiotix (NBTX) ha publicado su última actualización sobre derechos de voto y capital social al 31 de enero de 2025. La compañía reportó 47.426.851 acciones en circulación, con 49.208.659 derechos de voto teóricos y 49.186.541 derechos de voto ejercitables.
Nanobiotix es una empresa biotecnológica clínica en etapa avanzada con sede en París, Francia, que cotiza tanto en Euronext París como en el Nasdaq Global Select Market. La compañía se especializa en enfoques terapéuticos basados en la física y posee más de 25 familias de patentes en tres plataformas de nanotecnología enfocadas en oncología, biodisponibilidad y biodistribución, y trastornos del sistema nervioso central.
Nanobiotix (NBTX)는 2025년 1월 31일 기준으로 최신 투표권 및 자본 업데이트를 발표했습니다. 회사는 47,426,851주가 유통 중이며, 49,208,659개의 이론적 투표권과 49,186,541개의 행사 가능한 투표권을 보고했습니다.
Nanobiotix는 프랑스 파리에 본사를 두고 있는 후기 단계의 임상 생명공학 회사로, 유로넥스트 파리 및 나스닥 글로벌 셀렉트 마켓에 이중 상장되어 있습니다. 이 회사는 물리학 기반의 치료 접근 방식을 전문으로 하며, 종양학, 생체이용률 및 생체분포, 중추신경계 장애에 중점을 둔 세 가지 나노기술 플랫폼에서 25개 이상의 특허 패밀리를 보유하고 있습니다.
Nanobiotix (NBTX) a publié sa dernière mise à jour concernant les droits de vote et le capital social au 31 janvier 2025. La société a rapporté 47.426.851 actions en circulation, avec 49.208.659 droits de vote théoriques et 49.186.541 droits de vote exerçables.
Nanobiotix est une entreprise de biotechnologie clinique en phase avancée, dont le siège est à Paris, France, cotée à la fois sur Euronext Paris et sur le Nasdaq Global Select Market. L'entreprise se spécialise dans des approches thérapeutiques basées sur la physique et détient plus de 25 familles de brevets sur trois plateformes de nanotechnologie axées sur l'oncologie, la biodisponibilité et la biodistribution, ainsi que sur les troubles du système nerveux central.
Nanobiotix (NBTX) hat am 31. Januar 2025 sein neuestes Update zu Stimmrechten und Kapital veröffentlicht. Das Unternehmen berichtete von 47.426.851 ausstehenden Aktien, mit 49.208.659 theoretischen Stimmrechten und 49.186.541 ausübbaren Stimmrechten.
Nanobiotix ist ein biopharmazeutisches Unternehmen in der späten klinischen Phase mit Hauptsitz in Paris, Frankreich, das sowohl an der Euronext Paris als auch am Nasdaq Global Select Market gelistet ist. Das Unternehmen ist auf physikbasierte therapeutische Ansätze spezialisiert und besitzt mehr als 25 Patentfamilien über drei Plattformen der Nanotechnologie, die sich auf Onkologie, Bioverfügbarkeit und Biodistribution sowie Störungen des zentralen Nervensystems konzentrieren.
- Owns portfolio of over 25 patent families across three nanotechnology platforms
- Dual-listed on major exchanges (Euronext Paris and Nasdaq)
- None.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Feb. 12, 2025 (GLOBE NEWSWIRE) --
Paris, France, February 12, 2025
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| January 31, 2025 | 47,426,851 | 49,208,659 | 49,186,541 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | ||
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com | |
| Media Relations | ||
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com | |
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Attachment
FAQ
How many shares does Nanobiotix (NBTX) have outstanding as of January 31, 2025?
What is the difference between NBTX theoretical and exercisable voting rights?
How many patent families does Nanobiotix own and in what areas?
When did Nanobiotix (NBTX) get listed on Nasdaq Global Select Market?
